Journal of Dermatological Science
Volume 58, Issue 1 , Pages 78-80 , April 2010

Polymorphisms of FAS and FAS ligand genes and risk of skin cancer

  • Abrar Qureshi

      Affiliations

    • Clinical Research Program, Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States
    • Channing Laboratory of the Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States
    • Corresponding Author InformationCorresponding author at: Clinical Research Program, Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, 45 Francis St., Boston, MA, United States. Tel.: +1 617 525 7233.
  • Hongmei Nan

      Affiliations

    • Channing Laboratory of the Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States
    • Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Harvard School of Public Health, Boston, MA, United States
  • Jiali Han

      Affiliations

    • Clinical Research Program, Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States
    • Channing Laboratory of the Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States
    • Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Harvard School of Public Health, Boston, MA, United States

Received 4 July 2009

References 

  1. Armstrong BK, Kricker A, English DR. Sun exposure and skin cancer. Australas J Dermatol. 1997;38(Suppl. 1):S1–S6
  2. Banerjee G, Gupta N, Kapoor A, Raman G. UV induced bystander signaling leading to apoptosis. Cancer Lett. 2005;223(2):275–284
  3. Aragane Y, Maeda A, Cui CY, Tezuka T, Kaneda Y, Schwarz T. Inhibition of growth of melanoma cells by CD95 (Fas/APO-1) gene transfer in vivo. J Invest Dermatol. 2000;115(6):1008–1014
  4. Erb P, Ji J, Wernli M, Kump E, Glaser A, Büchner SA. Role of apoptosis in basal cell and squamous cell carcinoma formation. Immunol Lett. 2005;100(1):68–72
  5. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol. 1997;34(8–9):577–582
  6. Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003;63(15):4327–4330
  7. Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol. 2003;170(1):132–138
  8. Han J, Colditz GA, Hunter DJ. Risk factors for skin cancers: a nested case–control study within the Nurses’ Health Study. Int J Epidemiol. 2006;35(6):1514–1521
  9. Nelson HH, Kelsey KT, Bronson MH, Mott LA, Karagas MR. Fas/APO-1 promoter polymorphism is not associated with non-melanoma skin cancer. Cancer Epidemiol Biomarkers Prev. 2001;10(7):809–810
  10. Li C, Larson D, Zhang Z, Liu Z, Strom SS, Gershenwald JE, et al. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics. 2006;16(4):253–263

☆ Grant Support: K07CA10897, CA122838 and CA132175.

PII: S0923-1811(10)00027-7

doi: 10.1016/j.jdermsci.2010.01.003

Journal of Dermatological Science
Volume 58, Issue 1 , Pages 78-80 , April 2010

Article Tools